Nothing Special   »   [go: up one dir, main page]

EA201991105A1 - Методы оценки риска с использованием общей и специфической неклеточной днк - Google Patents

Методы оценки риска с использованием общей и специфической неклеточной днк

Info

Publication number
EA201991105A1
EA201991105A1 EA201991105A EA201991105A EA201991105A1 EA 201991105 A1 EA201991105 A1 EA 201991105A1 EA 201991105 A EA201991105 A EA 201991105A EA 201991105 A EA201991105 A EA 201991105A EA 201991105 A1 EA201991105 A1 EA 201991105A1
Authority
EA
Eurasian Patent Office
Prior art keywords
total
specific non
risk assessment
cellular dna
assessment methods
Prior art date
Application number
EA201991105A
Other languages
English (en)
Inventor
Аой Томита Митчелл
Майкл Митчелл
Карл Стамм
Original Assignee
Дзе Медикал Колледж Оф Висконсин, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2017/030293 external-priority patent/WO2017190106A1/en
Application filed by Дзе Медикал Колледж Оф Висконсин, Инк. filed Critical Дзе Медикал Колледж Оф Висконсин, Инк.
Publication of EA201991105A1 publication Critical patent/EA201991105A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2560/00—Nucleic acid detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к способам и композициям для оценки риска путем определения уровней общих и специфических неклеточных нуклеиновых кислот (таких как ДНК) у индивидуума. Описанные здесь способы и композиции могут быть применены для определения риска развития такого состояния, как отторжение трансплантата.
EA201991105A 2016-11-02 2017-11-02 Методы оценки риска с использованием общей и специфической неклеточной днк EA201991105A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662416689P 2016-11-02 2016-11-02
PCT/US2017/030293 WO2017190106A1 (en) 2016-04-29 2017-04-29 Multiplexed optimized mismatch amplification (moma)-target number
PCT/US2017/059808 WO2018085603A1 (en) 2016-11-02 2017-11-02 Methods for assessing risk using total and specific cell-free dna

Publications (1)

Publication Number Publication Date
EA201991105A1 true EA201991105A1 (ru) 2020-01-27

Family

ID=62076613

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991105A EA201991105A1 (ru) 2016-11-02 2017-11-02 Методы оценки риска с использованием общей и специфической неклеточной днк

Country Status (10)

Country Link
US (1) US20190367972A1 (ru)
EP (1) EP3535413A1 (ru)
JP (1) JP2019534016A (ru)
CN (1) CN110114477A (ru)
AU (1) AU2017355464A1 (ru)
CA (1) CA3042696A1 (ru)
EA (1) EA201991105A1 (ru)
IL (1) IL266382A (ru)
MX (1) MX2019005199A (ru)
WO (1) WO2018085603A1 (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9424392B2 (en) 2005-11-26 2016-08-23 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
US11339429B2 (en) 2010-05-18 2022-05-24 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
US9677118B2 (en) 2014-04-21 2017-06-13 Natera, Inc. Methods for simultaneous amplification of target loci
US11408031B2 (en) 2010-05-18 2022-08-09 Natera, Inc. Methods for non-invasive prenatal paternity testing
US11326208B2 (en) 2010-05-18 2022-05-10 Natera, Inc. Methods for nested PCR amplification of cell-free DNA
US11332785B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
CA3207599A1 (en) 2010-05-18 2011-11-24 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
WO2012108920A1 (en) 2011-02-09 2012-08-16 Natera, Inc Methods for non-invasive prenatal ploidy calling
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
CN106460070B (zh) 2014-04-21 2021-10-08 纳特拉公司 检测染色体片段中的突变和倍性
US11479812B2 (en) 2015-05-11 2022-10-25 Natera, Inc. Methods and compositions for determining ploidy
US11485996B2 (en) 2016-10-04 2022-11-01 Natera, Inc. Methods for characterizing copy number variation using proximity-litigation sequencing
WO2018085597A1 (en) * 2016-11-02 2018-05-11 Medical College Of Wisconsin, Inc. Methods for assessing risk using mismatch amplification and statistical methods
US10011870B2 (en) 2016-12-07 2018-07-03 Natera, Inc. Compositions and methods for identifying nucleic acid molecules
US11773434B2 (en) 2017-06-20 2023-10-03 The Medical College Of Wisconsin, Inc. Assessing transplant complication risk with total cell-free DNA
WO2019118926A1 (en) 2017-12-14 2019-06-20 Tai Diagnostics, Inc. Assessing graft suitability for transplantation
AU2019251504A1 (en) 2018-04-14 2020-08-13 Natera, Inc. Methods for cancer detection and monitoring by means of personalized detection of circulating tumor DNA
WO2019217918A1 (en) * 2018-05-10 2019-11-14 The Medical College Of Wisconsin, Inc. Multiplexed optimized mismatch amplification (moma)-cancer risk assessment with non-cancer associated targets
US11525159B2 (en) 2018-07-03 2022-12-13 Natera, Inc. Methods for detection of donor-derived cell-free DNA
US11931674B2 (en) * 2019-04-04 2024-03-19 Natera, Inc. Materials and methods for processing blood samples
WO2021207244A1 (en) * 2020-04-06 2021-10-14 The Medical College Of Wisconsin, Inc. Methods for assessing the severity of, and for inhibiting, pro-inflammatory responses with total cell-free dna
US20240229136A9 (en) * 2021-02-25 2024-07-11 Natera, Inc. Methods for detection of donor-derived cell-free dna in transplant recipients of multiple organs

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2496720T3 (pl) * 2009-11-06 2021-01-11 The Board Of Trustees Of The Leland Stanford Junior University Nieinwazyjna diagnoza odrzucenia przeszczepu u pacjentów z przeszczepem narządu
CN102892901B (zh) * 2010-03-24 2015-11-25 凸版印刷株式会社 利用竞争性引物的目标碱基序列的检测方法
US10131947B2 (en) * 2011-01-25 2018-11-20 Ariosa Diagnostics, Inc. Noninvasive detection of fetal aneuploidy in egg donor pregnancies
CA3209140A1 (en) * 2012-04-19 2013-10-24 The Medical College Of Wisconsin, Inc. Highly sensitive surveillance using detection of cell free dna
US20140242582A1 (en) 2013-02-28 2014-08-28 Ariosa Diagnostics, Inc. Detection of genetic abnormalities using ligation-based detection and digital pcr
WO2014194113A2 (en) * 2013-05-29 2014-12-04 Chronix Biomedical Detection and quantification of donor cell-free dna in the circulation of organ transplant recipients
ES2726650T3 (es) * 2014-03-14 2019-10-08 Caredx Inc Métodos de monitorización de terapias inmunosupresoras en un receptor de trasplante
EP3521454A1 (en) * 2014-05-09 2019-08-07 LifeCodexx AG Detection of dna that originates from a specific cell-type and related methods
WO2016001411A1 (en) * 2014-07-03 2016-01-07 Multiplicom N.V. Methods for non-invasive detection of transplant health or rejection
EP3209797B1 (en) * 2014-10-20 2018-12-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for screening a subject for a cancer
WO2016123698A1 (en) * 2015-02-06 2016-08-11 Uti Limited Partnership Diagnostic assay for post-transplant assessment of potential rejection of donor organs
JP2018514219A (ja) * 2015-04-30 2018-06-07 メディカル カレッジ オブ ウィスコンシン インコーポレイテッド 無細胞ｄｎａを評価するための多重／最適化ミスマッチ増幅（ｍｏｍａ）−リアルタイムｐｃｒ
EP3449018A4 (en) * 2016-04-29 2019-11-06 The Medical College of Wisconsin, Inc. REAL-TIME PCR WITH MULTIPLEXED OPTIMIZED MISMATCH AMPLIFICATION (MOMA) FOR THE EVALUATION OF FETAL WELL-BEING

Also Published As

Publication number Publication date
US20190367972A1 (en) 2019-12-05
EP3535413A1 (en) 2019-09-11
IL266382A (en) 2019-06-30
CA3042696A1 (en) 2018-05-11
JP2019534016A (ja) 2019-11-28
AU2017355464A1 (en) 2019-05-30
CN110114477A (zh) 2019-08-09
WO2018085603A1 (en) 2018-05-11
MX2019005199A (es) 2019-10-14

Similar Documents

Publication Publication Date Title
EA201991105A1 (ru) Методы оценки риска с использованием общей и специфической неклеточной днк
EA201892489A1 (ru) Число мишеней для мультиплексной оптимизированной амплификации с несоответствиями (moma)
EA201792389A1 (ru) Пцр в реальном времени для мультиплексной оптимизированной амплификации с несоответствиями (moma) и для оценки неклеточной днк
MX2020001809A (es) Metodos para determinar acido desoxirribonucleico circulante de donante sin genotipo de donante.
EA201992001A1 (ru) Композиции и способы повышения экспрессии генов
BR112017017025A2 (pt) métodos e composições para analizar componentes celulares
EA201692157A1 (ru) Синтез двухцепочечных нуклеиновых кислот
BR112018002848A2 (pt) método, aparelho, mídia de armazenamento não transitório, programa de computador, kit para medir níveis de expressão de seis ou mais genes-alvo da via de sinalização celular
EA201890619A1 (ru) КОМПОЗИЦИИ iRNA ЛИГАНДА 1 БЕЛКА ЗАПРОГРАММИРОВАННОЙ ГИБЕЛИ КЛЕТОК 1 (PD-L1) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EA201790769A1 (ru) Определение уровней гликозаминогликанов методом масс-спектрометрии
EA201791184A1 (ru) Днк-примеси в композиции, содержащей парвовирусный вирион
BR112016027475A2 (pt) kit, dispositivo e método para a detecção de câncer pancreático
EA201892491A1 (ru) Пцр в реальном времени с мультиплексной оптимизированной амплификацией неправильно спаренных оснований (moma) для анализа злокачественных новообразований
AR105618A1 (es) Metilación del promotor del ligando al receptor de muerte programada (pd-l1) en cáncer
EA201792080A1 (ru) Гуманизированные анти-c1s антитела и способы их применения
WO2017044993A3 (en) Nucleic acid analysis by joining barcoded polynucleotide probes
MX2016016742A (es) Ceramidas y su uso en el diagnostico de enfermedad cardiovascular (ecv).
BR112014026440A2 (pt) assays, methods and apparatus for assessing rna disruption
MX2022013471A (es) Metodo y composiciones de deteccion y cuantificacion de acido nucleico.
EA201891478A1 (ru) Способы и композиции для оценки риска возникновения рака
EA201991506A1 (ru) Системы и способы для тестирования и скрининга с использованием связанных с соединениями субстратов
EA201691702A1 (ru) Химерные белки мти
AR104805A1 (es) Métodos y composiciones para evaluar la capacidad de respuesta de los cánceres a los inhibidores de bet
MX2019011702A (es) Ensayos de inmunogenicidad mejorados.
DK3207374T3 (da) Fremgangsmåde og system til bestemmelse af koncentrationen af en analyt i en fluidprøve